Related Experiment Video

Updated: Jan 3, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

361

Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells

Jeeyun Lee1, Inkyoung Lee, Chaehwa Park

  • 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Biochemical and Biophysical Research Communications
|December 1, 2005
PubMed

Insights

Low-dose lovastatin induces cancer cell aging and cell cycle arrest in prostate cancer. Geranylgeranyl pyrophosphate (GGPP) or mevalonate addition, and RhoA modulation, reversed these effects, suggesting a new therapeutic avenue.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Lovastatin, a cholesterol synthesis inhibitor, targets 3-hydroxy 3-methylglutaryl coenzyme A reductase.
  • It prevents the production of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), crucial for cell signaling in proliferation and migration.
  • Emerging evidence suggests lovastatin possesses anti-cancer properties across various tumor types.

Purpose of the Study:

  • To investigate the anti-cancer effects of low-dose lovastatin on human prostate cancer cells.
  • To elucidate the mechanisms underlying lovastatin-induced cell cycle arrest and senescence.
  • To explore the role of specific cholesterol precursors and RhoA signaling in these processes.

Main Methods:

  • Treatment of human prostate cancer cells (PC-3) with low-dose lovastatin.
  • Addition of GGPP, mevalonate, or FPP to assess their impact on lovastatin effects.
  • Transfection of PC-3 cells with constitutively active RhoA (caRhoA) to evaluate RhoA's role.

Main Results:

  • Low-dose lovastatin induced senescence and G1 cell cycle arrest in human prostate cancer cells.
  • The addition of GGPP or mevalonate, but not FPP, prevented lovastatin-induced G1 arrest and senescence.
  • Constitutively active RhoA expression reversed lovastatin-induced senescence in PC-3 cells.

Conclusions:

  • Lovastatin's anti-cancer effect in prostate cancer involves inducing senescence and G1 cell cycle arrest.
  • GGPP and mevalonate, but not FPP, can counteract lovastatin's effects, highlighting the importance of specific isoprenoids.
  • RhoA signaling modulation appears critical in mediating lovastatin-induced senescence in prostate cancer cells.

More Related Videos

A Quantitative Measurement of Reactive Oxygen Species and Senescence-associated Secretory Phenotype in Normal Human Fibroblasts During Oncogene-induced Senescence13:59

A Quantitative Measurement of Reactive Oxygen Species and Senescence-associated Secretory Phenotype in Normal Human Fibroblasts During Oncogene-induced Senescence

Published on: August 12, 2018

8.5K
RhoC GTPase Activation Assay09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

12.9K

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
160
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K